Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | +0.63% | -2.69% | +4.84% |
Sales 2024 * | 94.02M 128M | Sales 2025 * | 72.9M 99.52M | Capitalization | 108M 147M |
---|---|---|---|---|---|
Net income 2024 * | -24M -32.76M | Net income 2025 * | -43M -58.7M | EV / Sales 2024 * | 1.15 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.48 x |
P/E ratio 2024 * |
-5.49
x | P/E ratio 2025 * |
-4.21
x | Employees | 121 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on CytomX Therapeutics, Inc.
1 day | +0.63% | ||
1 week | -2.69% | ||
Current month | -25.46% | ||
1 month | -24.42% | ||
3 months | +0.93% | ||
6 months | +46.40% | ||
Current year | +4.84% |
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 58 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 1.62 | +1.89% | 48 599 |
24-04-26 | 1.59 | -0.63% | 249,227 |
24-04-25 | 1.6 | -1.84% | 286,317 |
24-04-24 | 1.63 | -2.98% | 350,911 |
24-04-23 | 1.68 | +0.60% | 290,181 |
Delayed Quote Nasdaq, April 29, 2024 at 11:18 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.84% | 108M | |
-2.32% | 103B | |
+1.94% | 95.28B | |
+1.60% | 22.15B | |
-15.29% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-12.85% | 16.05B | |
+4.42% | 13.68B | |
+35.50% | 12.17B |
- Stock Market
- Equities
- CTMX Stock